Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last week:

‍Blogs :

‍Dr. Rifkin Reviews Dreamm-7 Trial Data in Relapsed Myeloma

Dr. Siegel Explores Mezigdomide's Early Potential in Relapsed Myeloma

Patient Profile: 72-Year-Old Male with Relapsed/Refractory Multiple Myeloma (RRMM)

Behind the Scenes: Patient Education and Decision-Making for CAR T Therapy

Drs. Baljevic and Cortes Preview Upcoming Studies and Data from ASH 2024.

A High-Risk Myeloma Patient's Journey to CAR T: Clinical and Personal Insights

Dr. Kaddoura Highlights Genomic Insights for IGH/CCND1+ Myeloma on Venetoclax

CEPHEUS Trial: Daratumumab-VRd in Transplant-Ineligible Multiple Myeloma Results

Dr. Landgren Discusses Tocilizumab Prophylaxis for Relapsed/Refractory Multiple Myeloma

Clinical Experience in CAR-T for Early Relapsed MM: CARTITUDE-4 Insights

Dr. Kumar Discusses Key Myeloma Treatment Considerations Following NCCN Guideline Updates

Myeloma, GVHD, and NHL Updates: Insights from Drs Rajkumar, Farhadfar, Smith

Overview of Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma (R/R MM)

‍Also at MCH the News and Tweets never stop flowing!

Join Us at www.mycancerhaven.org

‍The Team @ MCH

Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.